Acute Myeloid Leukemia Clinical Trial
Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML
Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet DailyÃ—5 in Cycle 1 followed by IV decitabine 20 mg/m^2 DailyÃ—5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, subjects will continue to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the subject discontinues treatment or withdraws from the study.
This Phase 3 study will establish PK equivalence of ASTX727 to IV decitabine in approximately 118 evaluable subjects. Eligible subjects will receive both study treatments: oral investigational drug ASTX727, and IV decitabine, as follows: subjects will be randomly assigned 1:1 to receive ASTX727 or IV decitabine in Cycle 1 and then cross over to the other therapy in Cycle 2.
In the ASTX727 cycle, subjects will receive the ASTX727 tablet DailyÃ—5. Serial PK measurements (blood draws) will be done on Days 1, 2, and 5, along with pre-dose PK assessments on Days 1-5 and an assessment at 3 hours post dose on Day 3. Subjects will be required to fast from food for 4 hours on days when receiving ASTX727: at least 2 hours before and 2 hours after dosing.
In the IV decitabine cycle, subjects will receive a 1-hour infusion of IV decitabine 20 mg/m^2 DailyÃ—5. Serial PK measurements will be done on Days 1 and 5, along with pre-dose and 1-hour post-infusion assessments on Day 3.
In Cycles â‰¥3, subjects will receive the ASTX727 tablet DailyÃ—5 in 28-day cycles. (No PK assessments will be done from Cycle 3 onward.)
Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent before the first study-specific procedure; specifically able to comply with the PK assessment schedule during the first 2 treatment cycles.
Men or women â‰¥18 years who are candidates to receive IV decitabine according to FDA or European Medicines Agency (EMA) approved indications:
In North America: Participants with MDS previously treated or untreated with de novo or secondary MDS, including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic Scoring System (IPSS) int-1, -2, or high-risk MDS.
In Europe: Participants with de novo or secondary AML, as defined by the World Health Organization (WHO) criteria, who are not candidates for standard induction chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Adequate organ function defined as follows:
Hepatic: Total or direct bilirubin â‰¤2 Ã— upper limit of normal (ULN); aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) â‰¤2.5 Ã— ULN.
Renal: serum creatinine â‰¤1.5 Ã— ULN or calculated creatinine clearance or glomerular filtration rate >50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
No major surgery within 30 days of first study treatment.
Life expectancy of at least 3 months.
Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of non-childbearing potential are those who have had a hysterectomy or bilateral oophorectomy, or who have completed menopause, defined as no menses for at least 1 year AND either age â‰¥65 years or follicle-stimulating hormone levels in the menopausal range.
Subjects and their partners with reproductive potential must agree to use effective contraceptive measures during the study and for 3 months after the last dose of study treatment. Effective contraception includes methods such as oral contraceptives or double-barrier method (eg, use of a condom AND diaphragm, with spermicide).
Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC) counts.
Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia, sepsis, or systemic infection in the 30 days before screening.
Treatment with any investigational drug or therapy within 2 weeks of study treatment, or 5 half-lives, whichever is longer, before the first dose of study treatment, or ongoing clinically significant adverse events (AEs) from previous treatment.
Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose of study treatment.
Concurrent MDS therapies, including lenalidomide, erythropoietin, cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these agents is permitted, provided that completion is at least 1 week before the first dose of study treatment.)
Poor medical risk because of other conditions such as uncontrolled systemic diseases, active uncontrolled infections, or comorbidities that may put the patient at risk of not being able to complete at least 2 cycles of treatment.
Known significant mental illness or other condition, such as active alcohol or other substance abuse or addiction, that in the opinion of the investigator predisposes the subject to high risk of noncompliance with the protocol.
Rapidly progressive or highly proliferative disease (total white blood cell count of >15 Ã— 10^9/L) or other criteria that render the subject at high risk of requiring intensive cytotoxic chemotherapy within the next 3 months.
Life-threatening illness or severe organ system dysfunction, such as uncontrolled congestive heart failure or chronic obstructive pulmonary disease, or other reasons including laboratory abnormalities, which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ASTX727, or compromise completion of the study or integrity of the study outcomes.
Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer or breast cancer under control with hormone therapy, or other cancer from which the subject has been disease free for at least 2 years.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 81 Locations for this study
Anniston Alabama, 36207, United States
Phoenix Arizona, 85054, United States
Tucson Arizona, 85715, United States
Fountain Valley California, 92708, United States
Los Angeles California, 90007, United States
New Haven Connecticut, 06510, United States
Washington District of Columbia, 20007, United States
Boca Raton Florida, 33322, United States
Fort Lauderdale Florida, 33308, United States
Miami Beach Florida, 33140, United States
Chicago Illinois, 60612, United States
Chicago Illinois, 60637, United States
Quincy Illinois, 62301, United States
Indianapolis Indiana, 46237, United States
Louisville Kentucky, 40207, United States
Baltimore Maryland, 21287, United States
Bethesda Maryland, 20817, United States
Farmington Hills Michigan, 48334, United States
Grand Rapids Michigan, 49503, United States
Rochester Minnesota, 55905, United States
Hackensack New Jersey, 07601, United States
Bronx New York, 10467, United States
Buffalo New York, 14263, United States
Lake Success New York, 11042, United States
New York New York, 10065, United States
Canton Ohio, 44718, United States
Columbus Ohio, 43210, United States
Portland Oregon, 20817, United States
Pittsburgh Pennsylvania, 15224, United States
Pittsburgh Pennsylvania, 15232, United States
Charleston South Carolina, 29414, United States
Nashville Tennessee, 37232, United States
Dallas Texas, 75246, United States
Dallas Texas, 75390, United States
Houston Texas, 77030, United States
Houston Texas, 77030, United States
Salt Lake City Utah, 84124, United States
Kennewick Washington, 99336, United States
Seattle Washington, 98109, United States
Salzburg , 05020, Austria
Vienna , 01130, Austria
Wels , 4600, Austria
Edmonton Alberta, T6G 2, Canada
Halifax Nova Scotia, B3H 2, Canada
Hamilton Ontario, L8V 1, Canada
Ottawa Ontario, K1H8L, Canada
Toronto Ontario, M4N 3, Canada
Toronto Ontario, M5G 2, Canada
MontrÃ©al Quebec, H1T 2, Canada
Ostrava Poruba, 708 0, Czechia
Brno , 62500, Czechia
Praha 10 ÄŒeskÃ¡ Republika, 10034, Czechia
Lyon Rhone, 69008, France
Mulhouse , 68100, France
Freiburg im Breisgau Baden, 79106, Germany
Marburg Hesse, 35033, Germany
Lubeck Schleswig-Holstein, 23538, Germany
Braunschweig , 38114, Germany
DÃ¼sseldorf , 40479, Germany
Halle , 06120, Germany
Leisnig , 04103, Germany
Debrecen , 4032, Hungary
KaposvÃ¡r , 7400, Hungary
Pecs , 7400, Hungary
Szeged , 6725, Hungary
Alessandria , 15121, Italy
Firenze , 50134, Italy
Milan , 20122, Italy
Novara , 28100, Italy
Rome , 00144, Italy
Vicenza , 36100, Italy
Oviedo Asturias, 33011, Spain
Santander Cantabria, 39008, Spain
CÃ¡ceres , 10003, Spain
Granada , 18012, Spain
L'Hospitalet De Llobregat , 08909, Spain
Madrid , 28007, Spain
Madrid , 28027, Spain
Madrid , 28041, Spain
Pamplona , 31008, Spain
Salamanca , 37007, Spain
ValÃ¨ncia , 46026, Spain
Oxford Oxfordshire, OX3 7, United Kingdom
Manchester , M20 4, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.